Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Price Passes Above 200-Day Moving Average – Should You Sell?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.10 and traded as high as $2.67. Sonoma Pharmaceuticals shares last traded at $2.58, with a volume of 35,479 shares trading hands.

Sonoma Pharmaceuticals Price Performance

The company has a fifty day moving average of $2.74 and a two-hundred day moving average of $2.10. The stock has a market capitalization of $3.45 million, a P/E ratio of -0.52 and a beta of 1.41.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 1.95% of the company’s stock.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.